A Study of Intravenous XMT-1107 in Patients With Advanced Solid Tumors (XMT-1107)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01011972
Recruitment Status : Completed
First Posted : November 11, 2009
Last Update Posted : January 31, 2018
Information provided by (Responsible Party):
Mersana Therapeutics

Brief Summary:
XMT-1107 has been shown in nonclinical studies to slow the growth of tumors. These effects may result from blocking the growth of new blood vessels that help the tumors survive.

Condition or disease Intervention/treatment Phase
Neoplasm Metastasis Drug: XMT-1107 Phase 1

Detailed Description:
This is an open-label, ascending-dose study of XMT-1107 administered intravenously over 90 minutes every 21 days (1 cycle). Blood sampling for PK analyses will be performed immediately prior to dosing and after dosing. Adverse events will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria (CTC) version 4.0 (CTCAE v4.0)

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 52 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Study of the Safety and Pharmacokinetics of XMT-1107 Administered as an Intravenous Infusion Once Every Three Weeks to Patients With Advanced Solid Tumors
Actual Study Start Date : March 2010
Actual Primary Completion Date : September 2013
Actual Study Completion Date : September 2013

Arm Intervention/treatment
Experimental: XMT-1107
Dose escalation groups of XMT-1107, I.V. (in the arm) beginning at 6 mg/m^2, doubling in dose to 24 mg/m^2, then 40 mg/m^2, then 60 mg/m^2, then 80 mg/m^2 with subsequent doses at 33% of the previous until disease progression or unacceptable side effects are experienced.
Drug: XMT-1107
6 mg XMT-1107 administered by I.V. (in the vein) administered over 90 min, once every 21 days : until progression or unacceptable toxicity develops
Other Name: conjugated XMT-1191

Primary Outcome Measures :
  1. The primary objective of this study is to determine the maximum tolerated dose of XMT-1107 when given via IV once every three weeks. [ Time Frame: Adverse events are assessed during each treatment cycle. ]

Secondary Outcome Measures :
  1. Assess the pharmacokinetics (PK) of XMT-1107 and its release product [ Time Frame: Samples for PK are collected during Cycle 1 and prior to each subsequent treatment cycle ]
  2. Determine the recommended Phase 2 dose of XMT-1107 [ Time Frame: Throughout Cycle 1 ]
  3. Assess the safety of XMT-1107. [ Time Frame: Throughout Cycle 1 ]
  4. Observe for evidence of anti-tumor activity by XMT-1107. [ Time Frame: Course of study ]
  5. Monitor the effect of XMT-1107 on MetAP2 inhibition in leukocytes from patients [ Time Frame: Cycle 1 and Cycle 2 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient must have a histological diagnosis of advanced solid tumor and must be refractory to standard therapy or have no effective therapy.
  • Measurable or evaluable disease.
  • At least 42 days since administration of mitomycin or nitrosoureas and 28 days since any other chemotherapy, investigational agent, and/or radiation therapy.
  • Age ≥ 18 years old.
  • Have the following laboratory values:

    • Absolute neutrophil count (ANC) ≥ 1500 cells/mm3
    • Platelet count ≥ 100,000 cells/mm3
    • Hemoglobin ≥ 9 g/dL
    • Serum creatinine ≤ 1.5 mg/dL or calculated creatinine clearance ≥ 60 mL/min (Calculated by Cockroft and Gault method. Creatinine clearance (mL/min) = (140-age) x weight (kg)/72 x (serum creatinine in mg/dL) = ml**/min (**for females, multiply results by 0.85))
    • Total bilirubin ≤ 1.5 mg/dL or ≤ upper limit of normal (ULN)
    • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times the institutional upper limit of normal (ULN) or ≤ 5 times ULN of liver metastases are present
    • Prothrombin time (PT) and partial thromboplastin time (PTT) ≤ 1.5 times the ULN
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1.
  • Life expectancy of at least 3 months.
  • Signed informed written consent.

Exclusion Criteria:

  • Known brain metastases (either currently or previously).
  • Peripheral neuropathy ≥ Grade 2.
  • Ataxia ≥ Grade 1.
  • Cognitive disturbance ≥ Grade 1.
  • History of seizures.
  • Patients known to be human immunodeficiency virus (HIV) positive.
  • Active infections requiring IV antibiotics or serious intercurrent illness, including hepatitis B or C.
  • Unstable angina, recent myocardial infarction (within the previous 6 months), or use of ongoing maintenance therapy for life-threatening arrhythmia.
  • Known hypersensitivity to this class of drugs.
  • Pregnant or nursing women, women who are of childbearing potential and are not using an effective method of either barrier or hormonal contraceptives. Men who are not using an effective method of barrier contraceptive, or who would not be willing to continue to use these effective methods for the duration of the study.
  • Patients who have had a major surgical procedure (not including mediastinoscopy), open biopsy, or significant traumatic injury ≤ 4 weeks prior to beginning treatment.
  • Patients with proteinuria at screening as demonstrated by either:

    1. urine protein creatinine (UPC) ratio ≥ 1.0 at screening OR
    2. urine dipstick for proteinuria ≥ 2+ (patients discovered to have ≥ 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection, and must demonstrate ≤ 1 g of protein/24 hours to be eligible)
  • Patients with a serious non-healing wound, active ulcer, or untreated bone fracture.
  • Patients with history of hematemesis or hemoptysis (defined as having bright red blood of ½ teaspoon or more per episode) ≤ 1 month prior to study enrollment.
  • Inadequately controlled hypertension (defined as systolic blood pressure >140 mm Hg and/or diastolic blood pressure > 90 mm Hg while on antihypertensive medications). Initiation of antihypertensive agents is permitted provided adequate control is documented at least 1 week prior to beginning study treatment.
  • Significant vascular disease (e.g., aortic aneurysm requiring surgical repair, or recent peripheral arterial thrombosis) ≤ 6 months prior to Day 1 of treatment.
  • History of stroke or transient ischemic attack ≤ 6 months prior to beginning treatment.
  • Any prior history of hypertensive crisis or hypertensive encephalopathy.
  • History of abdominal fistula or gastrointestinal perforation ≤ 6 months prior to Day 1 of beginning treatment.
  • QTc interval > 470 milliseconds as calculated by Bazett's formula.
  • Any issue that, in the opinion of the Investigator, would render the patient unsuitable for study participation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01011972

United States, Maryland
University of MD Greenbaum Cancer Center
Baltimore, Maryland, United States, 21201
United States, Massachusetts
Dana Farber Cancer Institute (DFCI)
Boston, Massachusetts, United States, 02115
Beth Israel Deaconess Medical Center (BIDMC)
Boston, Massachusetts, United States, 02215
United States, Tennessee
Sarah Cannon Research Institute (SCRI)
Nashville, Tennessee, United States, 37203
Sponsors and Collaborators
Mersana Therapeutics
Principal Investigator: Johana Bendell, MD Sara Cannon Research Institute
Principal Investigator: Geoffrey Shapiro, MD Dana-Farber Cancer Institute
Principal Investigator: Edward Sausville, MD University of Maryland, Greenbaum Cancer Center

Responsible Party: Mersana Therapeutics Identifier: NCT01011972     History of Changes
Other Study ID Numbers: MER-1107-001
First Posted: November 11, 2009    Key Record Dates
Last Update Posted: January 31, 2018
Last Verified: September 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Mersana Therapeutics:
Dose escalation
Phase 1
maximum tolerated dose

Additional relevant MeSH terms:
Neoplasm Metastasis
Neoplastic Processes
Pathologic Processes